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Abstract In most pathology laboratories worldwide,
formalin-fixed paraffin embedded (FFPE) samples are the
only tissue specimens available for routine diagnostics.
Although commercial kits for diagnostic molecular pathol-
ogy testing are becoming available, most of the current
diagnostic tests are laboratory-based assays. Thus, there is a
need for standardized procedures in molecular pathology,
starting from the extraction of nucleic acids. To evaluate the
current methods for extracting nucleic acids from FFPE
tissues, 13 European laboratories, participating to the
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DOI 10.1007/s00428-010-0917-5European FP6 program IMPACTS (www.impactsnetwork.
eu), isolated nucleic acids from four diagnostic FFPE
tissues using their routine methods, followed by quality
assessment. The DNA-extraction protocols ranged from
homemade protocols to commercial kits. Except for one
homemade protocol, the majority gave comparable results
in terms of the quality of the extracted DNA measured by
the ability to amplify differently sized control gene frag-
ments by PCR. For array-applications or tests that require
an accurately determined DNA-input, we recommend using
silica based adsorption columns for DNA recovery. For
RNA extractions, the best results were obtained using
chromatography column based commercial kits, which
resulted in the highest quantity and best assayable RNA.
Quality testing using RT-PCR gave successful amplification
of 200 bp–250 bp PCR products from most tested tissues.
Modifications of the proteinase-K digestion time led to
better results, even when commercial kits were applied. The
results of the study emphasize the need for quality control
of the nucleic acid extracts with standardised methods to
prevent false negative results and to allow data comparison
among different diagnostic laboratories.
Keywords FFPE.Multicentre study.Molecular analyses
standardisation.PCR.DNA.RNA.Isolation
Introduction
One of the major challenges in oncology is a correct
prediction of individual recurrence risk and the prediction
of efficacy and safety of therapy. Histopathology is only
partly able to mirror and predict the clinical behaviour of
individual tumours. Through the application of molecular
tools, otherwise indistinguishable tumour subgroups have
been identified and the definition of a precise gene mutation
pattern has highlighted classes of tumours with clinical
prognostic implications [1]. Moreover the application of
molecular tests such as real time PCR based assays has
become feasible thanks to the use of formalin-fixed paraffin
embedded samples [2], which represent the most valuable
source of diagnostic materials. As a consequence, in the
near future molecular approaches in formalin fixed and
paraffin embedded (FFPE) material will become part of the
routine process of cancer diagnostics. At the present time
most of the methods applied in molecular pathology are
laboratory-based assays and commercial kits not directly
intended for diagnostic purposes. Therefore there is a need
to establish guidelines with standardised procedures for
molecular methods, starting from an analysis of the
currently used methods of nucleic acids extraction.
This collaborative study includes 13 European laborato-
ries of the IMPACTS group (www.impactsnetwork.eu) and
was conducted to evaluate the performance of nucleic acids
extractions using the same formalin-fixed paraffin-
embedded specimens. The aim of the study is to assess if
the different methodologies used for nucleic acids extrac-
tion in different laboratories might affect the results.
Materials and methods
Four cases of formalin-fixed paraffin-embedded tissues
were distributed to the participants in the study in two
rounds. In detail, the Trieste group delivered one colorectal
cancer specimen during the first control round. The Berlin
group delivered an ovary cancer sample and the Graz group
delivered two lung cancer cases in the second control
round. Surgical specimens with a large amount of tissue
were used to ensure to have sufficient material for the
multicentre analysis. Comparable tissue areas distributed in
2 to 4 sections of 5 μm in thickness were used per test and
distinct tissue blocks of the same cases were selected for
RNA and DNA extractions. The sections were collected
sequentially: each following section was given to a different
participant in order to obtain the most homogeneous
representative tissues in all the different laboratory tests.
Tissue slides were sent under vacuum at room temperature.
The colon cancer samples were dated 2002, while the lung
and ovarian cancer specimens were dated 2008. Each
laboratory used the protocol that was routinely used for
standard DNA and/or RNA extractions as reported in
Supplemental 1, 2 and 3. Although interesting, it was
technically not feasible to test the different extraction
methods by the diagnostic laboratories. The homemade
protocols for the extractions are referred to detailed
references, while the commercial kits are referred to the
manufacturer’s manuals. Each nucleic acid extract was
quantified by means of Nanodrop (ThermoScientific). The
total amount of nucleic acids and A260/A280 results were
recorded for each extract. The quality assessment for DNA
extracts was performed by the use of the BIOMED-2
control gene PCR method as previously described [3]. This
method is based on a multiplex PCR resulting in a ladder of
fragments (100, 200, 300, and 400 bp) to check the quality
and amplifiability of DNA from FFPE materials.
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310 Virchows Arch (2010) 457:309–317In detail, the undiluted DNA sample and 100 ng of the
sample were amplified. In case no amplified band was
detected (like the colon and lung specimens from partici-
pant 1), multiple DNA concentrations (10, 50, 200 ng) were
amplified as well. The BIOMED-2 control gene PCR was
run for all samples in one laboratory (Molecular Pathology,
RUNMC, Nijmegen) and analyzed by electrophoresis on
agarose gel.
For the first control round, RNA (colon cancer speci-
men) quality assessment by RT-PCR was performed in each
laboratory using their routinely method with their usual
fragment length amplification. All the protocols were based
on DNA digestion and cDNA synthesis by the use of the
random priming approach. In the second control round, for
RNA extracts, DNase treatments and cDNA synthesis were
all performed in one lab (Trieste), as previously reported
[4], after re-quantification of RNA. Complementary DNAs
were then submitted in dry ice to Munich (LMU) for PCR
analysis as described hereafter. Quality test for RNA was
performed by amplifying different fragments of PBGD
(Porphobilinogen deaminase) (150 and 250 bases), B2M
(Beta-2-microglobulin) (200 bases) and β-actin (103 bases)
housekeeping genes. As negative control, pure DNAse
treated RNAs of a representative number of samples were
used in the PCR reactions for specificity testing. Because
the ovarian cancer samples yielded by far the lowest
amount of RNA and neither PBGD nor B2M was
detectable by PCR subsequent to standard reverse tran-
scription procedure using random primer, these RNA
samples were reverse transcribed using a PCR-target
specific primer (β-actin forward, see below). The β-actin
specific cDNA was amplified by PCR resulting in an
amplification product of 103 bases. PCR products were
analysed by agarose gel electrophoresis (3% w/v). For all
PCR reactions, 200 ng cDNA (50 ng control cDNA, cell
line) and the AmpliTaq Gold DNA polymerase (Applied
Biosystems, Darmstadt, Germany) were used with 40
amplification cycles (10 min. 94°C; 40 cycles of
30 sec. 94°C, 30 sec. 60°C, 1 min. 72°C and one cycle
10 min. 72°C). For the β- a c t i na n dP B G D( 2 5 0b p
amplicon) specific PCR, 1.5 mM MgCl2 and 0.2 mM
dNTP-mix were used. The 150 bp amplicon PBGD-PCR
employed 2.0 mM MgCl2 and the B2M specific PCR
(200 bp) 2.5 mM MgCl2. The primer sequences were as
follows:
PBGD (250 bp): forward: 5′-CTGGTAACGGCAAT
GCGGCT-3′, reverse: 5′-TTCTTCTCCAGGG CATGTTC-3′;
PBGD (150 bp): forward: 5′-TGCCAGAGAAGAGTGT
GGTG-3′, reverse: 5′-AT GATGGCACTGAACTCCTG-3′;
B2M (200 bp): forward: 5′-GTTGACTTACTGAAGAATGG
AG-3′,reverse:5′-GATGCTGCTTACATGTCTCG-3′;β-actin
(103 bp): forward: 5′-TTGCGGAT GTCCACGTCA-3′,r e -
verse: 5′-GCCCTGAGGCACTCTTCCA-3′
Results
DNA
Thirteen European participants were involved in the valida-
tion testing of DNA. The laboratories originating in Austria,
Croatia, Germany, Italy, Portugal, Spain, Switzerland and The
Netherlandswerekeptanonymousandwererankedaccording
to the protocol type. The methods used by each participant
were divided into 3 major groups, since the protocols within
each group were similar.
1. DNA extraction with precipitation of the DNA either
by NaAc/EtOH (Participants 1, 2, 5) or by isopropanol
(Participants 3, 4). Participant 4 took part only in the
second round of DNA validation (lung and ovary
cancer specimens).
2. DNA extraction without further precipitation or purifi-
cation (Participants: 6, 7 and 8, the latter only for the
colon cancer sample)
3. DNA extraction using silica based adsorption columns
for purifying DNA (Participants: 9, 10, 11, 12 and 13).
Details on the used protocols are provided in Supple-
mental Tables 1 and 2. The criteria used for evaluation of
the DNA extracts were: 1) the DNA yield obtained by the
extraction and 2) the DNA quality assessed by the purity
measured by spectral-photometry (A260/A280)a n db y
BIOMED-2 gene control PCR to test PCR-amplifiability.
The median amounts of extracted DNA for each sample are
reported in detail in Table 1 and Fig. 1, and show that the
total amount of DNA extracted was highly dependent on
the method used. The highest DNA-yields were obtained by
the use of homemade methods that do not employ further
purification of the DNA (Table 1, protocol type 2). Note
that in these DNA extracts, the measured concentration
does not reflect the actual DNA quantity because of the co-
presence of RNA and proteins debris, as it is apparent from
the A260/A280 ratio (Supplemental Table 1). Thus, the DNA
yield and concentration of these specimens are only
indicative. A lower DNA yield was obtained when using
column based methods or homemade methods including a
DNA precipitation step. This trend was shown for all the
analyzed specimens.
Differences in the purity of the DNA extracts hardly
affect the PCR-amplifiability (Table 2 and Fig. 2). The
quality of the DNA extracted from the lung specimens
allowed amplification of the 300 bp band of the control
gene PCR for all protocols. Some protocols allowed
amplification of the 400 bp fragment, although this band
was only faintly detected. For the colon sample, many
protocols allowed DNA-amplification of the 200 bp band as
the maximal amplifiable length, while two homemade
protocols only successfully amplified the smallest sized
Virchows Arch (2010) 457:309–317 311control amplicon of 100 bp. From one participant using a
homemade protocol, DNA extracts from colon and lung
specimens did not allow amplification of the control genes.
Regarding the DNA extraction procedures characterised by
purification steps, it seems there is no clear correlation
among quantities of detected DNA and PCR performance;
even for low amounts of extracted DNA the PCR
performance was good.
RNA
The validation of RNA isolation methods was performed by
10 participants from 8 European countries (Austria, Germany,
Croatia, Italy, Portugal, Spain, Switzerland and The Nether-
lands). The participants were kept anonymous using the
numbering of the DNA validation tests. The extraction
protocols can be divided into 3 major groups as follows
(numbered sequentially according to DNA protocols):
4. RNA extraction using phenol extraction and isopropanol
precipitation- homemade protocols (Participants 2, 4, 5)
5. RNA extraction using phenol extraction and isopropa-
nol precipitation- commercial mono-phase solutions
(Participants 8, 11)
6. RNA extraction using silica based columns for purifica-
tion(Participants:3,4onlyforColonCancersample,6,7,
9, 12)
The criteria for assessing the quality of the RNA
isolation method were: 1) the RNA yield and 2) the
RNA quality determined by purity detection using
spectral-photometry (A260/A280) and by amplification
methods. The RNA was isolated from a single case of
colorectal cancer, two lung cancer cases and one ovary
Table 1 Results on the nucleic acids extraction quantities
DNA yield by protocol type RNA yield by protocol type
Sample Protocols type 1 Protocols type 2 Protocols type 3 Protocols type 4 Protocol type 5 Protocols type 6
Colon ca. 72.8 µg (70-80) 237 µg (145-274) 46.5 µg (39-76) 19.5 µg (17-22) 38.4 µg (30-47) 48.4 µg (12-70)
Ovarian ca. 17.4 µg (11-26) 85.8 µg (70-101) 8.1 µg (4-9) 1.8 µg (1.5-4.9) 2.6 µg (1.6-3.6) 5.7 µg (2.5-6.8)
Lung ca 1 35.1 µg (27-51) 144 µg (125-163) 15.6 µg (16-19) 9.2 µg (5-22) 41.0 µg (37-45) 32.3 µg (8-41)
Lung ca. 2 25.9 µg (16-37) 160 µg (134-186) 16.9 µg (15-19) 8.9 µg (6-9) 20.8 µg (19-23) 22.9 µg (7-40)
For each sample the median amount of extracted nucleic acid and the 25th and 75th centiles (in brackets) with respect of the protocol type are
reported.
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Fig. 1 Bar graph representing
the total amount of extracted
DNA from colon cancer, ovarian
cancer and lung cancer (2) speci-
mens by the use of different
protocoltypes.Lightgreybarsare
referred to protocol type 1 (DNA
extraction with precipitation
step); medium grey bars are re-
ferred to protocol type 2 (DNA
extraction without purifications
steps) and dark grey bars are
referred to protocol type 3 (DNA
extraction with commercial kits
based on the use of silica based
columns)
312 Virchows Arch (2010) 457:309–317cancer tissue. The median amount of extracted RNA is
reported in Table 1 and Fig. 3. Regarding the protocol
type, the RNAyield was higher with the use of commercial
kits based on silica column purification (protocol type 6),
followed by the use of commercial solutions and the
homemade protocols. The Qiagen RNeasy FFPE kit using
an extended proteinase-K digestion time revealed the best
performance regarding the yield (Supplemental Table 4).
However, when the Qiagen RNeasy FFPE kit was used by
different participants, remarkable differences in RNA yield
were observed (Supplemental Tables 3 and 4,F i g .3
participant 12 vs. 7).
The RNA quality was measured by RNA purity
detection using spectral-photometry (A260/A280). The high-
est purity was obtained by silica based column purification
procedures (protocol type 6) (Qiagen RNeasy FFPE kit and
Roche High Pure RNA Paraffin kit) with the exception of
the Gentra kit and was followed by the homemade protocol
(protocol type 4) based on phenol extraction and isopropa-
nol precipitation. The commercial solution method (proto-
col type 5) gained the least pure RNA measured by the
A260/A280 absorption ratio. To further validate the RNA
quality a standardized PCR procedure was used with four
different amplicon lengths (103 bp, 150 bp, 200 bp, 250 bp)
after standard reverse transcription. The original RNA of
the samples was used as negative control resulting in no
PCR product. Taken together, the column based commer-
cial kits (protocol type 6 - Qiagen RNeasy FFPE kit and
Roche High Pure RNA Paraffin kit) yielded the best
assayable RNA quality (Table 3, Fig. 4). Interestingly the
performance of the RNA in the RT-PCR reaction did not
always correlate with RNA purity data, as RNA obtained
by commercial solutions with the least pure RNA (protocol
type 5) performed better than RNA extracted by homemade
protocols (protocol type 4; see Table 3).
Discussion
Diagnostic methodologies need per definition a basic level of
standardization in order to obtain concordance in the responses
among hospitals. Immunohistochemistry (IHC) is the most
widely used method to detect proteins in FFPE tissues for
diagnostic purposes. Despite the standardization of immuno-
histochemical staining protocols, some factors could still vary
among samples and laboratories, such as tissue fixation
(duration), choice of antibodies, and the threshold for interpre-
tation of positive immunostaining, which may dramatically
Fig. 2 BIOMED-2 control gene PCR results of the extracted DNAs in
duplicateofgroup9,6and2(protocoltype3,2and1respectively).DNA
was extracted from ovary (a), lung 1 (b) and lung 2 (c). The size of the
amplified products is indicated. The lowest thick band represents
primer-dimer products
Protocol Type Participant Colon Ca. Ovarian Ca. Lung Ca. 1 Lung Ca. 2
1 1 0 200 0 0
1 2 200 100 400 300
1 3 100 100 300 300
1 4 nd 100 300 300
1 5 200 100 400 400
2 6 200 100 400 300
2 7 200 100 400 400
38
a 100 100 400 300
3 9 200 100 400 300
3 10 200 100 300 400
3 11 200 100 300 300
3 12 nd 100 300 300
3 13 nd 100 400 300
Table 2 Performance of the
extracted DNAs in the
BIOMED-2 gene control PCR
The performance is expressed in
base pairs referred to the longest
PCR fragment that was amplified.
The 400 bp band, when detected,
was only weakly present.
nd= not determined, these par-
ticipants (4, 12 and 13) did not
send their DNA samples for
general quality control testing.
a This participant used protocol
type 2 for the colon cancer sample,
as underlined.
Virchows Arch (2010) 457:309–317 313affect test accuracy and reproducibility. In any case IHC is
considered an accurate diagnostic method because there are
guidelines and inter-laboratory quality controls through the
cross-testing of cases that guaranteethe reliability of theassays.
Nowadays, there is great interest and need for molecular
pathology tests in order to better characterize pathologies and
better define the individual patient profile for tailored therapy.
In the present study, we have systematically compared the
results of different homemade and commercial protocols for
DNA and RNA extraction on the same set of FFPE tissue
specimens used in several laboratories in order to define
reliable criteria on nucleic acid extraction from FFPE tissues.
The design of this multicentre study allows determining
the specific effects of the different extraction protocols,
since the quality control experiments and interpretation of
the multicentric results were performed in a single
laboratory. Nonetheless, we cannot entirely exclude the
possible effects of additional parameters, such as different
technicians and laboratory equipments, which may influ-
ence the results. However, as the extractions were
performed by experienced technicians in molecular diag-
nostic laboratories, we anticipate a minimal effect of these
parameters.
The FFPE tissues used in this study originate from
routine diagnostics of three different pathology depart-
ments. Hence it may well be possible that fixation time and
the size of the tissue pieces used, which is important for the
fixation rate, varies. Formalin not only cross-links proteins
and nucleic acids, it also modifies RNA by adding mono-
methylol groups to all the four bases blocking reverse
transcription [5]. However it has been shown that the
efficiency of extracting amplifiable RNA and DNA from
FFPE tissue is inversely proportional to the fixation time [6,
7] and thus standardized fixation conditions are important.
This was not specifically addressed in the current study
since all laboratories used serial sections of the same tissue
block of each cancer tissue.
DNA
DNA extraction protocols that used purification of the
extracted DNA, either by precipitation (protocol type 1) or
by using silica-based columns (protocol type 3) gave
comparable results in terms of yield and purity of the
DNA. The apparent yield of DNA by the use of these
protocols is less comparable to protocols that do not
employ any purification (protocol type 2), which is not
surprising, since the measured DNA-concentration in the un-
purified samples reflects the presence of RNA and DNA.
Yield and concentration from protocols that do not employ
purification steps is thus not accuratesince degraded RNAs as
well as protein debris are also quantified, overestimating
thereby the real DNA amount.
The PCR-amplifiability of the DNA samples was not
drastically affected by the use of different DNA-extraction
protocols.Ourstudyshowedthatthemeasurementofamplify-
ability of the DNA by performance of the BIOMED-2 control
gene PCR is the preferred parameter, superior to spectropho-
tometrical determination of the A260/A280 ratio, to measure
DNA-quality for diagnostic molecular testing. In general,
DNA obtained from FFPE samples that allows amplification
of 300 bp is considered as good DNA-quality and can be
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Fig. 3 Bar graph representing
the total amount of extracted
RNA from colon cancer, ovarian
cancer and lung cancer (2)
specimens by the use of differ-
ent protocol types. Light grey
bars are referred to protocol type
4 (RNA extraction with home-
made protocols); medium grey
bars are referred to protocol type
5 (RNA extraction with mono-
phasic commercial solutions)
and dark grey bars are referred
to protocol type 6 (RNA extrac-
tion with commercial kits based
on the use of silica based
columns)
314 Virchows Arch (2010) 457:309–317used for many molecular tests, including clonality testing
using the BIOMED-2 primers and protocols [8]. Array
comparative genomic hybridization (aCGH) was successful
using DNA samples from FFPE tissues, which allowed
amplifying 200 bp in the BIOMED-2 control gene PCR [9].
Based on evaluation of the DNA-amplifyability, there is not a
single DNA-extraction protocol that is highly superior to
others. The majority of the DNA-extraction protocols, except
for the DNA-extraction protocol by participant 1, give similar
and comparable results. There was only a minor difference in
outcome, showing less performance of the DNA-extraction
protocol used by participants 3 and 8a. However, as this was
seen only in one of the four tested samples, there is no solid
reason to avoid the use of these protocols.
Upon selection of the protocol to use in a diagnostic
laboratory, also the requirements for the specific molecular
test should be taken into consideration. It should be realised
that molecular tests that require a standardized input of DNA,
shoulduse purifiedDNA-samples,allowingthemostaccurate
DNA-quantification. For complex multiplexed PCRs or tests
that require a specific accurate input of DNA per PCR test,
like B- /T-cell clonality assessment, [8], as well as for
application of array-CGH [6], MLPA-based tests [7], we
strongly recommend using type 3 protocols that use silica
based adsorption columns for purifying DNA.
For other molecular tests like PCR followed by direct
sequencing, however, purification may not be essential. The
use of protocols without further purification (protocol type 2)
has an additional advantage, it is more rapid and less
expensive compared to DNA-protocols that employ purifica-
tionsteps.We therefore recommendthe use ofa simpleDNA-
protocol, such as the type 2 protocols (DNA extractions
without further purification or precipitation), for general
molecular tests as mutation and translocation detection.
Whichever the method used, it is highly recommended to
employ only optimized and controlled reagents. This can be
an important source of result variability.
RNA
The RNA isolation methods affected the yield of the
extracted RNA, even when extraction conditions (protein-
ase K incubation time and temperature) were comparable
(Supplemental Table 3). Proteinase K digestion is an
important step affecting the RNA yield. In fact, we
observed that an extended digestion time resulted in a
more efficient extraction, especially from colon and ovarian
tumour tissue using the Qiagen RNeasy FFPE kit. This is
consistent with previous reports demonstrating that increas-
Fig. 4 B2M housekeeping gene specific RT-PCR results of the
extracted RNAs of the group 2, 11, 6, 3, 7 and 12 (protocol type 4, 5
and four times 6, respectively). RNA was extracted from ovary (a),
lung 1 (b) and lung 2 (c). The PCR products were separated in 3 %
(w/v) agarose gels. The size of the amplification products is indicated
(200 bp). M: size marker (50 bp DNA Ladder, Invitrogen, Karlsruhe,
Germany)
Table 3 Results on RNA quality assessment by PCR
Protocol
Type
Participant Colon
Ca
a
Ovarian
Ca
Lung
Ca. 1
Lung
Ca. 2
4 2 150 103 200 200
44
b 200 103 200 200
4 5 160 103 200 200
5 8 127 103 - 250
5 11 250 103 250 200
6 3 160 103 150 -
6 6 185 103 250 250
6 7 200 103 250 250
6 9 110 103 - -
6 12 293 103 250 250
Results are expressed in base pairs referred to the longest amplifiable
PCR product.
The larger the PCR product, the better the RNA quality was considered.
a no PCR for longer amplicon was performed in the first round of testing;
the analysed housekeeping genes were: ACTB (Beta-Actin), PBGD
(Porphobilinogen deaminase), PDHB (Pyruvate dehydrogenase, beta),
GUSB (Glucuronidase, beta), FGFR3 (Fibroblast growth factor receptor 3).
b This participant used for colon cancer specimen the protocol type 6, as
underlined.
(-) no PCR product was obtained (150 bp or larger amplicons).
Virchows Arch (2010) 457:309–317 315ing proteinase K digestion time improved the RNAyield [6,
10, 11]. Formalin fixation preserves cellular structures by
crosslinking biomolecules and thus traps nucleic acids and
prevents the extraction of amplifiable RNA and DNA. By
extending the digestion time to at least 16 hours, proteinase
K is thought to release protein cross-linked nucleic acids
more efficiently to permit subsequent RNA/DNA isolation,
e.g. by column based methods [6]. Surprisingly, extended
proteinase K incubation had no effect on the RNA quality
evaluated by RT-PCR.
The RNA quality assessment by spectral photometry did
not correlate with the maximum amplifiable length (Tables 1
and 3). The ratio A260/280 is an indicator of possible
contaminants [12] and the presence of inhibitors for
subsequent reactions, however, this measurement is highly
variable [13] and does not assess the length of the RNA
extracted. Similarly, the widely used quality assessment by
capillary electrophoresis (Bioanalyzer or Experion) is not
predictive of the utility of RNA samples isolated from
FFPE tissue in molecular analyses, since the most limiting
factor for RT-PCR and presumably other enzymatic
procedures, is the chemical modification of RNA by
formaldehyde, which is not resolved by electrophoretic
assays [10, 14].
Regarding the high degree ofdegradation ofRNA inFFPE
tissues, the ability of amplifying 250 bp PCR-fragments
indicates RNA of very good quality. Nevertheless, the
successful amplification of target mRNA fragments ≥200 bp
in length was considered good RNA quality [11, 15]. All
isolation methods resulted in RNA of useful quality for
expression analyses in archival and diagnostic tissues, since
shorter amplicons are sufficient for quantitative PCR [15–
17]. This study reveals that column based methods (protocol
type 6) provided best RNA quality assessed by RT-PCR
from most of the tissues. Moreover these methods, in
comparison to homemade protocols and commercial mono-
phasic solutions, are less time-consuming by omitting the
precipitation step to isolate the RNA. Small adjustments of
the manufacturer’s instruction (e.g. proteinase K digestion)
may have caused inter-laboratory variability both in RNA
quantity and quality, which is consistent with earlier reports
demonstrating that different results were obtained by
different groups using the same commercial kits [10, 15].
Although homemade RNA extraction methods (protocol
type 4) or commercial solutions (protocol type 5) may be
suitable for certain applications in research and diagnostics
usingshortamplicons(below160bp),ourresultsdemonstrate
that among the analyzed methods , particularly the Qiagen
RNeasy FFPE kit including an extended proteinase-K
digestion period is recommended. Due to the observed inter-
laboratory variability, further standardization of the techni-
ques, including commercial kits, isrecommended for research
and diagnostic applications in molecular pathology.
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